Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ruth O'Regan

Showing results (1-10 of 76) with videos related to

Pageof 8
Sort By:
Clinical Advances in Hematology & Oncology : H&O|April 12, 2021
Treatment goals in the management of HER2-positive metastatic breast cancerRuth O'Regan
Clinical Advances in Hematology & Oncology : H&O|April 12, 2021
Neratinib in early-stage breast cancer: clinical trial dataRuth O'Regan
Clinical Advances in Hematology & Oncology : H&O|March 10, 2012
Emerging nontaxane therapies for metastatic breast cancerRuth O'Regan
ACP Journal Club|March 17, 2006
Review: bisphosphonates prevent or delay skeletal events in women with advanced breast cancer and bone metastasesRuth O'Regan
Oncology (Williston Park, N.Y.)|April 5, 2011
Adjuvant anthracyclines: time for a change of heart?Ruth O'Regan
Clinical Breast Cancer|May 25, 2021
Introduction to Special IssueKari Wisinski, Ruth O'Regan
Therapeutics and Clinical Risk Management|January 25, 2013
New and emerging treatments for estrogen receptor-positive breast cancer: focus on everolimusElisavet Paplomata, Ruth O'Regan
Cancers|March 2, 2017
AR Signaling in Breast CancerBilal Rahim, Ruth O'Regan
Therapeutic Advances in Medical Oncology|July 25, 2014
The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkersElisavet Paplomata, Ruth O'Regan
Expert Opinion on Therapeutic Targets|April 12, 2011
mTOR inhibition in breast cancer: unraveling the complex mechanisms of mTOR signal transduction and its clinical implications in therapyRuth O'Regan, Natalyn Nicole Hawk
Pageof 8

Showing results (1-10 of 76) with videos related to

Sort By:
Pageof 8
Clinical Advances in Hematology & Oncology : H&O|April 12, 2021
Treatment goals in the management of HER2-positive metastatic breast cancerRuth O'Regan
Clinical Advances in Hematology & Oncology : H&O|April 12, 2021
Neratinib in early-stage breast cancer: clinical trial dataRuth O'Regan
Clinical Advances in Hematology & Oncology : H&O|March 10, 2012
Emerging nontaxane therapies for metastatic breast cancerRuth O'Regan
ACP Journal Club|March 17, 2006
Review: bisphosphonates prevent or delay skeletal events in women with advanced breast cancer and bone metastasesRuth O'Regan
Oncology (Williston Park, N.Y.)|April 5, 2011
Adjuvant anthracyclines: time for a change of heart?Ruth O'Regan
Clinical Breast Cancer|May 25, 2021
Introduction to Special IssueKari Wisinski, Ruth O'Regan
Therapeutics and Clinical Risk Management|January 25, 2013
New and emerging treatments for estrogen receptor-positive breast cancer: focus on everolimusElisavet Paplomata, Ruth O'Regan
Cancers|March 2, 2017
AR Signaling in Breast CancerBilal Rahim, Ruth O'Regan
Therapeutic Advances in Medical Oncology|July 25, 2014
The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkersElisavet Paplomata, Ruth O'Regan
Expert Opinion on Therapeutic Targets|April 12, 2011
mTOR inhibition in breast cancer: unraveling the complex mechanisms of mTOR signal transduction and its clinical implications in therapyRuth O'Regan, Natalyn Nicole Hawk
Pageof 8